Trikafta and Vancomycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trikafta (elexacaftor, ivacaftor, tezacaftor; ivacaftor) and Vancomycin (vancomycin). Common drug interactions include abdominal distension among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Trikafta and Vancomycin. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Trikafta?

Trikafta has active ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor. eHealthMe is studying from 11,852 Trikafta users. Check the latest studies of Trikafta.

What is Vancomycin?

Vancomycin has active ingredients of vancomycin. eHealthMe is studying from 17,165 Vancomycin users. Check the latest studies of Vancomycin.

On Jul, 10, 2026

19 people who take Trikafta and Vancomycin together, and have interactions are studied.

Trikafta and Vancomycin drug interactions.

What are the common drug interactions of Trikafta and Vancomycin, by gender? *:

female:

Abdominal distension
Weight increased
Alopecia (absence of hair from areas of the body)
Amenorrhoea (absence of a menstrual period in a woman of reproductive age)
Anger
Blood glucose decreased
Emotional poverty
Heart rate increased
Hepatic enzyme increased
Increased appetite

male:

Nausea (feeling of having an urge to vomit)
Pain in extremity
Joint injury
Sleep disorder
Thyroid disorder (thyroid diseases)
Abdominal distension
Abdominal pain upper
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Arthralgia (joint pain)
Back pain

What are the common drug interactions of Trikafta and Vancomycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Abdominal pain upper
Cough
Diarrhoea

20-29:

Respiratory disorder (respiratory disease)
Abdominal pain
Cystic fibrosis (disease of the secretary glands)
Paranasal sinus hypersecretion

30-39:

Fatigue (feeling of tiredness)
Abdominal distension
Headache (pain in head)
Abdominal pain upper
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Haematochezia (passage of stools containing blood)
Haemorrhage (bleeding)
Nephrolithiasis (calculi in the kidneys)
Weight increased

40-49:

n/a

50-59:

n/a

60+:

Drug eruption (adverse drug reaction of the skin)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Nausea (feeling of having an urge to vomit)
Pain in extremity
Sleep disorder
Thyroid disorder (thyroid diseases)
Weight increased
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pericarditis (inflammation of the pericardium)
Cellulitis (infection under the skin)

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 17 people, 89.47%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 2 people, 10.53%
Stress And Anxiety: 1 person, 5.26%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 1 person, 5.26%
Infection: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Trikafta and Vancomycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously